Scholarlink

Introduction <p>The SANTORINI study was a multicentre, observational, European study conducted after the publication of 2019 European Society of Cardiology (ESC) / European Atherosclerotic Society (EAS) lipid guidelines. The study sought to investigate lipid management in routine&#xa0;clinical practice in light of the guideline recommended low-density lipoprotein cholesterol (LDL-C) goals.</p> Methods <p>Patients aged ≥ 18&#xa0;years, assessed as having ‘high’ or ‘very high’ cardiovascular (CV) risk and requiring lipid-lowering therapy (LLT) were enrolled across seven investigational sites in Ireland.</p> Results <p>Of the 100 enrolled patients, data for 98, aged 65.2 ± 11.7&#xa0;years, were available for analysis. A majority of 65.3% patients were classified as very high CV risk, while the remaining 34.7% as high CV risk. Risk classification in 52% of all enrolled patients was based on clinical experience, while 47% on the 2019 ESC/EAS guidelines. Between baseline to 1-year follow-up, proportion of patients on statin monotherapy increased from 71.4 to 84.7% and statin + ezetimibe combination therapy from 4.1 to 7.1%, respectively. LLT intensification/escalation occurred in 17.7% of patients in the high CV risk group and 21.9% in the very high CV risk group. Only a minority of patients achieved their 2019 ESC/EAS-defined LDL-C goals at baseline (25.7%), with a slight increase at 1-year follow-up (29.7%).</p> Conclusions <p>In the Irish cohort of the SANTORINI study, only&#xa0;a minority of high and very high CV risk patients achieved their LDL-C goals. LLT intensification and the broader use of combination LLT might be useful strategies to increase the proportion of patients attaining their LDL-C goals.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Lipid-lowering therapy treatment regimens in high- and very high-risk patients for the prevention of cardiovascular events: results from the Irish cohort of the multinational, observational SANTORINI study

  • 期刊论文

  • 发表日期：

    2025年10月30日

查看全文
  • Himanshu Rai,
  • John Joseph Coughlan,
  • Daniel O’Callaghan,
  • Richard Sheahan,
  • Ross Murphy,
  • David Burke,
  • Eugene McFadden,
  • Dermot Nolan,
  • Roisin Colleran,
  • Abiola Hazeez-Agbaje,
  • Kausik K. Ray,
  • Alberico L. Catapano,
  • Robert A. Byrne

摘要

Introduction

The SANTORINI study was a multicentre, observational, European study conducted after the publication of 2019 European Society of Cardiology (ESC) / European Atherosclerotic Society (EAS) lipid guidelines. The study sought to investigate lipid management in routine clinical practice in light of the guideline recommended low-density lipoprotein cholesterol (LDL-C) goals.

Methods

Patients aged ≥ 18 years, assessed as having ‘high’ or ‘very high’ cardiovascular (CV) risk and requiring lipid-lowering therapy (LLT) were enrolled across seven investigational sites in Ireland.

Results

Of the 100 enrolled patients, data for 98, aged 65.2 ± 11.7 years, were available for analysis. A majority of 65.3% patients were classified as very high CV risk, while the remaining 34.7% as high CV risk. Risk classification in 52% of all enrolled patients was based on clinical experience, while 47% on the 2019 ESC/EAS guidelines. Between baseline to 1-year follow-up, proportion of patients on statin monotherapy increased from 71.4 to 84.7% and statin + ezetimibe combination therapy from 4.1 to 7.1%, respectively. LLT intensification/escalation occurred in 17.7% of patients in the high CV risk group and 21.9% in the very high CV risk group. Only a minority of patients achieved their 2019 ESC/EAS-defined LDL-C goals at baseline (25.7%), with a slight increase at 1-year follow-up (29.7%).

Conclusions

In the Irish cohort of the SANTORINI study, only a minority of high and very high CV risk patients achieved their LDL-C goals. LLT intensification and the broader use of combination LLT might be useful strategies to increase the proportion of patients attaining their LDL-C goals.